US Patent

US10973934 — Gadolinium bearing PCTA-based contrast agents

Composition of Matter · Assigned to Bracco Imaging SpA · Expires 2039-08-06 · 13y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects the RRR/SSS pair of enantiomers of Gd(PCTA-tris-glutaric acid) and their related compounds.

USPTO Abstract

The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutaric acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.

Drugs covered by this patent

Patent Metadata

Patent number
US10973934
Jurisdiction
US
Classification
Composition of Matter
Expires
2039-08-06
Drug substance claim
Yes
Drug product claim
No
Assignee
Bracco Imaging SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.